Ann: Mesoblast to File BLA for Ryoncil FDA Approval Next Week, page-123

Don’t worry Lopez. With the FDA having guided the company to the AA pathway for end stage ischemic HFrEF patients, having seen the clinical benefits of reduced GI bleeding that are significant enough to reduce mortality both in LVAD patients AND to make a difference in the generalised increased AVM observed in such patients pre-LVAD transplant, the company will make a big splash with Revascor being held out as a destimation therapy. If people are trying to play market risk by manipulating the stock, my strong sense is that they will be burnt, and badly so. Time will tell how much they will hurt. (See my reply this morning to @otherperspective for further detail and why the company has pivoted to talking about Revascor for end stage HFrEF patients, omitting references to “LVAD” in its recent presentation.)

https://onlinelibrary.wiley.com/doi/full/10.1002/ehf2.14433